By Wendy Diller
Alain Merieux, the owner, CEO, and chairman of bioMerieux SA , likes to say that he is on good...
As its traditional market in microbiology matures, bioMerieux is tryiing to branch out into broader areas of infectious diseases. But it is confronting a tough environment with lots of competition and rapid consolidation
By Wendy Diller
Alain Merieux, the owner, CEO, and chairman of bioMerieux SA , likes to say that he is on good...
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.
UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.